Basic Information
| LncRNA/CircRNA Name | HULC |
| Synonyms | HULC, HCCAT1, LINC00078, NCRNA00078 |
| Region | GRCh38_6:8435568-9294133 |
| Ensemble | ENSG00000251164 |
| Refseq | NR_004855 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | cell lines (LNCaP, PC3,DU145,RWPE-1), PCa tissues |
| Expression Pattern | up-regulated |
| Function Description | HULC expression was upregulated in PCa tissues and cell lines compared to adjacent non-tumor tissues and the normal prostate cell line RWPE-1. High HULC expression was positively associated with advanced clinicopathologic features and poor overall survival (OS) for PCa patients.HULC inhibition suppressed PCa cell growth and metastasis both in vitro and in vivo.Furthermore, HULC knockdown reduced N-cadherin and vimentin expression and increased E-cadherin expression in PCa cells.LncRNA HULC might play oncogenic roles in PCa progression, which provided a novel therapeutic strategy for PCa patients.lncRNA HULC enhanced epithelial mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1. |
| Pubmed ID | 29765457 |
| Year | 2018 |
| Title | High lncRNA HULC expression is associated with poor prognosis and promotes tumor progression by regulating epithelial-mesenchymal transition in prostate cancer. |
External Links
| Links for HULC | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |